Both our experimental as well as observational studies indicate that in vivo lymphovascular tumor emboli and their in vitro spheroid equivalent ...

Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 ...

THRAP3, STMN1, and GNA13—are overrepresented in blood cancers like acute myeloid leukemia (AML) and could prove to be novel ...

The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma.

Cancer is thought to be the second most prevalent and leading cause of mortality worldwide, affecting both men and women among other chronic diseases. While there are several treatment options ...

Cancer remains one of the leading global causes of mortality, with an estimated increase in cases due to lifestyle, ...

Cancer remains one of the leading global causes of mortality, with an estimated increase in cases due to lifestyle, environmental, and genetic ...

The Buffalo Bills select International Pathway Program offensive guard Travis Clayton in Round 7 of the 2024 NFL Draft with the No. 221 overall pick (via a trade with the Kansas City Chiefs).

In an interview with Targeted Oncology, Jacob Stein, MD, MPH, discussed nab-sirolimus and its impact on patients with ...

NUZ-001 works by inhibiting a key cellular pathway known as mTOR, which is crucial for regulating cell growth, proliferation, and a process called autophagy, which is how cells recycle and dispose ...